190 related articles for article (PubMed ID: 15746584)
21. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
22. Current treatment options in dermatofibrosarcoma protuberans.
Lemm D; Mügge LO; Mentzel T; Höffken K
J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
[TBL] [Abstract][Full Text] [Related]
23. Imatinib in the treatment of dermatofibrosarcoma protuberans.
Labropoulos SV; Razis ED
Biologics; 2007 Dec; 1(4):347-53. PubMed ID: 19707305
[TBL] [Abstract][Full Text] [Related]
24. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Sawyers CL
J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
[No Abstract] [Full Text] [Related]
25. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
Price VE; Fletcher JA; Zielenska M; Cole W; Viero S; Manson DE; Stuart M; Pappo AS
Pediatr Blood Cancer; 2005 May; 44(5):511-5. PubMed ID: 15503291
[TBL] [Abstract][Full Text] [Related]
26. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible?
Wang C; Luo Z; Zheng B; Chen Y; Cao X; Wang J; Zhang R; Shi Y
Eur J Cancer Prev; 2012 Nov; 21(6):585-7. PubMed ID: 23014697
[No Abstract] [Full Text] [Related]
28. Targeted therapy for dermatofibrosarcoma protuberans.
Abrams TA; Schuetze SM
Curr Oncol Rep; 2006 Jul; 8(4):291-6. PubMed ID: 17254529
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
30. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
Bianchini L; Maire G; Pedeutour F;
Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
[TBL] [Abstract][Full Text] [Related]
31. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
33. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
[TBL] [Abstract][Full Text] [Related]
35. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
McArthur GA
J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
37. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
39. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
40. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]